Xiaojun Jing

Beijing University of Posts and Telecommunications — China

Medicine · Health Sciences

29h-index11.2kcitations59works4.32yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Prostate Cancer Treatment and Research(17), Cancer-related molecular mechanisms research(12), Cancer-related gene regulation(12), Epigenetics and DNA Methylation(10), Cancer Genomics and Diagnostics(7)

Publications57 total

A Sensing Dataset Protocol for Benchmarking and Multi-Task Wireless Sensing
arXiv (Cornell University)·2025Open Access
Status epilepticus of carotid web after carotid artery stenting: A case report
Journal of International Medical Research·2025Open Access
The Potential Role of Neurogranin in Alzheimer’s Disease
Journal of Integrative Neuroscience·2025· 2 citedOpen Access
Spectrum Sensing Meets ISAC: An Spectrum Detection Scheme for ISAC Services Based on Improved Denoising Auto-Encoder and CNN
Applied Sciences·2025· 2 citedOpen Access
Inhibition of RAC1 activator DOCK2 ameliorates cholestatic liver injury via regulating macrophage polarisation and hepatic stellate cell activation
Biology Direct·2025· 5 citedOpen Access
The value of electroencephalography features in the prognostic evaluation of large hemispheric infarction patients at different time intervals
Neurological Sciences·2024
Development of Peptidomimetic Inhibitors of the ERG Gene Fusion Product in Prostate Cancer
Cancer Cell·2024· 1 citedOpen Access
Corrigendum to “Characterizing the Therapeutic Potential of a Potent BET Degrader in Merkel Cell Carcinoma” [Neoplasia, Volume 21, Issue 3 (2019) 322–330]
Neoplasia·2024· 1 citedOpen Access
Comprehensive proteogenomic characterization of rare kidney tumors
Cell Reports Medicine·2024· 39 citedOpen Access
Associations of Serum Isoleucine with Mild Cognitive Impairment and Alzheimer’s Disease
Annals of Geriatric Medicine and Research·2024Open Access
Corrigendum to “Characterizing the Therapeutic Potential of a Potent BET Degrader in Merkel Cell Carcinoma” [Neoplasia, Volume 21, Issue 3 (2019) 322–330]
Neoplasia·2024Open Access
Histopathologic and proteogenomic heterogeneity reveals features of clear cell renal cell carcinoma aggressiveness
Cancer Cell·2022· 184 citedOpen Access
The associations of serum valine with mild cognitive impairment and Alzheimer’s disease
Aging Clinical and Experimental Research·2022· 20 cited
The Associations of Serum Valine with Mild Cognitive Impairment and Alzheimer’s Disease
2021· 2 citedOpen Access
Correction: SPINK1 promotes colorectal cancer progression by downregulating Metallothioneins expression
Oncogenesis·2021· 3 citedOpen Access
Epigenetic driver mutations in ARID1A shape cancer immune phenotype and immunotherapy
Journal of Clinical Investigation·2020· 193 citedOpen Access
Characterizing the Therapeutic Potential of a Potent BET Degrader in Merkel Cell Carcinoma
Neoplasia·2019· 13 citedOpen Access
Epigenetic Reprogramming with Antisense Oligonucleotides Enhances the Effectiveness of Androgen Receptor Inhibition in Castration-Resistant Prostate Cancer
Cancer Research·2018· 57 citedOpen Access
miR-34a Regulates Expression of the Stathmin-1 Oncoprotein and Prostate Cancer Progression
Molecular Cancer Research·2017· 61 citedOpen Access
Development of Peptidomimetic Inhibitors of the ERG Gene Fusion Product in Prostate Cancer
Cancer Cell·2017· 22 cited
page 1 of 3Next →

Frequent Co-authors

Xuhong Cao(31), Arul M. Chinnaiyan(31), Saravana M. Dhanasekaran(22), Sooryanarayana Varambally(17), Nallasivam Palanisamy(16), Irfan A. Asangani(15), Qi Cao(14), Marcin Cieślik(14), Bushra Ateeq(13), Javed Siddiqui(12), Rohit Mehra(12), Scott A. Tomlins(11), John R. Prensner(10), Kenneth J. Pienta(10), Robert J. Lonigro(9), Arul M. Chinnaiyan(9), Matthew K. Iyer(9), Chandan Kumar‐Sinha(8), Christopher A. Maher(8), Xiaoju Wang(8)